Moderna Inc. (MRNA)
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna (MRNA 0.42%) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits.
Moderna: A Generational Opportunity for Investors in 2025
As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity in cutting-edge biotech.
Moderna shares move higher as investors look beyond Q4 losses to pipeline potential
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday's session as investors remained optimistic about the company's long-term strategy following mixed fourth quarter earnings. The company last week reported a wider-than-expected loss for Q4, as revenue surpassed expectations.
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
On Friday, Moderna Inc. MRNA reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago.
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?
Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.
A lot of concern around Moderna over next year or so, says Jefferies Michael Yee
Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition.
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Moderna (NASDAQ:MRNA ) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Ellie Merle - UBS Gena Wang - Barclays Michael Yee - Jefferies Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Tyler Van Buren - TD Cowen Luca Issi - RBC Capital Courtney Breen - Bernstein Edward Tenthoff - Piper Sandler Jessica Fye - J.P. Morgan Simon Baker - Redburn Atlantic Myles Minter - William Blair Tim Anderson - Bank of America Operator Good day, and thank you for standing by.
Moderna shares rise on quarterly revenue beat despite wider-than-expected loss
Moderna Inc (NASDAQ:MRNA, ETR:0QF) stock moved higher after the pharmaceutical firm posted mixed results for the fourth quarter. It reported a wider-than-expected loss per share of $2.91, compared to estimates of a loss per share of $2.73.
Moderna's Q4 Loss Wider Than Expected
Moderna (MRNA 2.91%), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the market for COVID vaccines shifts from government contracts to a seasonal commercial market.
Moderna has no 'visible path' to profitability, analyst says
Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91. Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight.
